It’s Human Nature To Want To Survive Cancer.
And the Human Immune System has revealed the way.

CAR T-Cell therapy is the biggest breakthrough in cancer therapy in 30 years.

Immunotherapy is using the patient immune system to fight cancer and it is transforming the field of oncology. Chimeric antigen receptor (CAR) T-cell therapy is the first cell-based immunotherapy approved by the FDA for the treatment of acute lymphoblastic leukemia (ALL) in children and young adults, as well as relapsed or refractory diffuse large B-cell lymphoma in adult patients.

This therapy gives new hope to patients for whom all other treatments have stopped working.

Cancer cells are able to grow and escape the immune system’s natural ability to kill cancer cells. CAR T-cells are reengineered to break down barriers and make them able to attack cancer cells again, harnessing the power of the immune system.

This represents a breakthrough that will revolutionize the field of oncology. This new treatment modality has shown remarkable activity in patients with leukemia or lymphoma who failed all existing therapies.

John Theurer Cancer Center at Hackensack University Medical Center has unparalleled expertise.

John Theurer Cancer Center at Hackensack University Medical Center is on the leading edge of cancer care and played a pivotal role in the developments that led to the approval of CAR T-cell therapy.

Our physicians are among the most experienced in treating advanced cancers with immunotherapy, including cell-based therapy. We are pioneers in blood and marrow stem cell transplantation and lead organizations that are defining the field—not just in the U.S., but also the world.

Collectively, our physician leaders at John Theurer Cancer Center have among the most hands-on experience in applied cell therapy in the world, having performed more than 30,000 transplants since 1981.

With 1,200 team members collaborating in a highly subspecialized and multidisciplinary environment, John Theurer Cancer Center understands the intricacies of the disease, the therapies, and the individual.

The most difficult to treat cancers require the most complex treatments, such as CAR-T cell therapy—which require the most experienced physicians to deliver them safely.

We’re building on our legacy to provide the next generation of cancer care.

When you have the most serious of cancers, you need specialized skill, experience and expertise. You need John Theurer Cancer Center at Hackensack University Medical Center.

To learn more, please visit jtcancercenter.org

Unmatched Clinical Expertise

Scott Rowley, M.D.: past president International Society for Cellular Therapy, and board of directors American Society for Blood and Bone Marrow Transplantation
Performed more than 7,000 transplants since 1981

Andrew Pecora, M.D.: past chairman Graft Engineering Committee ISHAGE and board of directors American Society for Blood and Bone Marrow Transplantation
Performed more than 5,000 transplants since 1985

David Siegel, M.D., Ph.D: internationally renowned expert, multiple myeloma
Performed more than 5,000 transplants since 1985

David Vesole, M.D., Ph.D: internationally renowned expert, multiple myeloma
Performed more than 5,000 transplants since 1987

Michele Donato, M.D.: chairperson Collection Standards FACT
Performed more than 4,000 transplants since 1991

Andre Goy, M.D.: internationally renowned expert, lymphoma
Performed more than 3,000 transplants since 1984

Alfred Gillio, M.D.: internationally renowned expert, pediatric hematology & oncology
Performed more than 1,000 transplants since 1984

A member of the Memorial Sloan Kettering – Hackensack Meridian Health Partnership